Last checked at 14 Oct 2010 15:00
|
| ||||
| TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi | ||||
|
|
| |||
| 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii | Proteome Sciences plc | |||
| 2 Reason for the notification (please tick the appropriate box or boxes): | ||||
| An acquisition or disposal of voting rights | Yes | |||
| An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
| |||
| An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
| |||
| An event changing the breakdown of voting rights |
| |||
| Other (please specify): |
|
| ||
| 3. Full name of person(s) subject to the notification obligation: iii | Sanofi-Aventis Deutschland GmbH | |||
| 4. Full name of shareholder(s) (if different from 3.):iv |
| |||
| 5. Date of the transaction and date on which the threshold is crossed or reached: v | 13 October 2010 | |||
| 6. Date on which issuer notified: | 14 October 2010 | |||
| 7. Threshold(s) that is/are crossed or reached: vi, vii | 4% | |||
| 8. Notified details: | ||||||||||||||||
| A: Voting rights attached to shares viii, ix | ||||||||||||||||
| Class/type of shares if possible using the ISIN CODE | Situation previous to the triggering transaction | Resulting situation after the triggering transaction | ||||||||||||||
| Number of Shares | Number of Voting Rights | Number of shares | Number of voting rights | % of voting rights x | ||||||||||||
| Direct | Direct xi | Indirect xii | Direct | Indirect | ||||||||||||
|
| 7,794,266 | 7,794,266 | 7,465,410 | 7,465,410 |
| 3.88% |
| |||||||||
| GB0003104196 | ||||||||||||||||
|
| ||||||||||||||||
| B: Qualifying Financial Instruments | ||||||||||||||||
| Resulting situation after the triggering transaction | ||||||||||||||||
| Type of financial instrument | Expiration date xiii | Exercise/ Conversion Period xiv | Number of voting rights that may be acquired if the instrument is exercised/ converted. | % of voting rights | ||||||||||||
|
|
|
|
|
| ||||||||||||
|
| ||||||||||||||||
| C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||||||||||||
| Resulting situation after the triggering transaction | ||||||||||||||||
| Type of financial instrument | Exercise price | Expiration date xvii | Exercise/ Conversion period xviii | Number of voting rights instrument refers to
| % of voting rights xix, xx
| |||||||||||
|
|
|
|
|
| Nominal | Delta | ||||||||||
|
|
| |||||||||||||||
|
| ||||||||||||||||
| Total (A+B+C) | ||||||||||||||||
| Number of voting rights | Percentage of voting rights | |||||||||||||||
| 7,465,410 | 3.88% | |||||||||||||||
| 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi | ||
|
| ||
|
| ||
| Proxy Voting: | ||
| 10. Name of the proxy holder: |
| |
| 11. Number of voting rights proxy holder will cease to hold: |
| |
| 12. Date on which proxy holder will cease to hold voting rights: |
| |
|
| ||
| 13. Additional information: |
| |
| 14. Contact name: | Juergen Blieke or Reiner May | |
| 15. Contact telephone number: | 0049 69 305 4703 or 0049 69 305 80202 | |